论文部分内容阅读
恶性淋巴瘤包括霍奇金病和非霍奇金淋巴瘤(NHL),两者均分为淋巴结来源和淋巴结外来源,而淋巴结外来源占NHL25%-50%,其中胃是最好发的部位。与胃癌相比,原发性胃淋巴瘤发病率低,在胃恶性肿瘤中占2%-8%,但有逐年升高的趋势,其发病率和病死率已居恶性肿瘤第五位。胃淋巴瘤的发病年龄大多超过50岁,但也有报道年轻患者的发病率有所上升。近年来,随着单克隆抗体研制成功,NHL的治疗取得了可喜的进步,美罗华即抗CD20单克隆抗体,是第一个被美国FDA批准进入临床治疗应用的单抗制剂。我院2003年6月开始开展美罗华联合CHOP方案治疗1例胃NHL,取得满意疗效,现报道如下。1资料与方法患者,女,31岁。因反复腹痛伴解黑便半个月余,拟“上
Malignant lymphomas include Hodgkin’s disease and non-Hodgkin’s lymphoma (NHL), both of which are classified as lymph node sources and extranodal sources of lymph nodes, while extranodal sources account for 25% -50% of NHL, with the stomach being the best site for development . Compared with gastric cancer, the incidence of primary gastric lymphoma is low, accounting for 2% -8% of gastric malignant tumors, but there is a trend of increasing year by year. The morbidity and mortality of this disease are the fifth highest in malignant tumors. The onset of gastric lymphoma is mostly over 50 years of age, but there are also reports of an increase in the incidence of young patients. In recent years, with the successful development of monoclonal antibodies, the treatment of NHL has made gratifying progress. Rituximab, the anti-CD20 monoclonal antibody, is the first monoclonal antibody approved by the FDA for clinical treatment. Our hospital began in June 2003 rituximab combined with CHOP regimen in the treatment of 1 case of gastric NHL, achieved satisfactory results, are reported below. 1 Materials and Methods Patients, female, 31 years old. Due to repeated abdominal pain associated with black half a month, to be ”on